跳至主要内容
临床试验/JPRN-UMIN000003855
JPRN-UMIN000003855已完成2 期

Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer) - Phase II study of CDDP/PEM/BEV for EGFR mutation negative stage III/IV non-small-cell lung cancer)

Departmnent of Thoracic Oncology Kanagawa Cancer Center0 个研究点目标入组 25 人开始时间: 2010年7月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Massive pleural effusion 2)Massive pericardial effusion 3)Double cancer 4)Severe complications; myocardial infarction, unstable angina, heart failure, uncontrolled hypertension, and unconrolled diabetis mellitus, uncontrolled infection, uncontrolled mental disease, SVC syndrome 5)Hemoptysis(more than 2.5ml), continuous or treatment-required bloody sputum 6)Invasion to large vessels, cavity in tumor 7)Brain metastsis 8)Under anti-coagulation therapy 9)Bleeding 10)Nephrosis 11)Uncured wound 12)Digestive tract ulcer, diverticulosis 13)Bone marrow suppression 14)Lung fibrosis 15)Pregnancy 16)Other inappropriate cases

研究者

发起方
Departmnent of Thoracic Oncology Kanagawa Cancer Center

相似试验